Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 with Paclitaxel and Bevacizumab in Advanced Gastric/GEJ Cancer
NCT07045805Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Progression-Free Survival up to 7 months and Dose-Limiting Toxicity. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07045805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07045805.